Clik here to view.
Cantor Fitzgerald raises target on Catamaran to $65
Cantor Fitzgerald analyst Tom Liston says the rise in specialty drug spending bodes well for Catamaran Corp.Cantor Fitzgerald analyst Tom Liston attended the Pharmacy Benefit Management Institute’s...
View ArticleClik here to view.
Catamaran posts another record year, but still has room to grow
The merger of Express Scripts and Medco created a leader in the PBM space that had combined revenues of $116-billion, topping number two CVS Caremark, whose revenues were $107-billion.The story of...
View ArticleClik here to view.
Cantor Fitzgerald says buy Catamaran aggressively on Q1 selloff
Cantor Fitzgerald analyst Tom Liston says that he views the fact that there was no further disclosure on the Cigna contract as positive, and now believes there is “an overwhelming probability” that the...
View ArticleClik here to view.
Catamaran’s deal with Cigna is “transformational” says Cantor Fitzgerald
Cantor Fitzgerald analysts Tom Liston and Justin Kew say Catamaran’s ten-year contract with Cigna is “transformational”. This morning, they raised their target on the stock, which they regard as a “top...
View ArticleClik here to view.
Cantor Fitzgerald analyst Tom Liston continues winning ways
Cantor Fitzgerald analyst Tom Liston’s top pick for 2013, Descartes Systems Group, is already up 27.9% so far this year. The gaudy numbers are nothing new for the man who has become one of Canada’s...
View ArticleClik here to view.
It’s time for BlackBerry to get out of the way of Canadian tech
“You’re a tech guy, huh? What about BlackBerry? Pretty bad, eh?” This is the reaction I often get when someone I meet finds out that what I do is all about Canadian technology. Today, I’m afraid to...
View ArticleClik here to view.
Industry trends point to growth for Catamaran, says Cantor Fitzgerald
Cantor Fitzgerald analyst Justin Kew says Catamaran can become a benefactor of the comprehensive health insurance reforms of the Affordable Care Act.Cantor Fitzgerald analyst Justin Kew attended the...
View ArticleClik here to view.
Catamaran is compelling at 52-week low, says Cantor Fitzgerald
Cantor Fitzgerald Canada analyst Justin Kew thinks Catamaran will continue to grow its market share at the expense of its two larger competitors, CVS and Express Scripts.Down more than 20% on the year,...
View ArticleClik here to view.
Catamaran is an outstanding long-term investment, says John Zechner
Portfolio manager John Zechner on BNN Tuesday.Catamaran (TSX:CCT) and Google couldn’t be further apart in terms of the corners of the technology space they occupy, but they have one thing in common,...
View ArticleClik here to view.
Catamaran spikes after $5.5-billion third quarter
Shares of Catamaran Corp. (TSX:CCT) are up today after the company reported Q3 results that bested expectations. Riding strong organic growth in its Pharmacy Benefit Management business, the company’s...
View ArticleCantor Fitzgerald raises target on Catamaran to $65
Cantor Fitzgerald analyst Tom Liston attended the Pharmacy Benefit Management Institute’s (PBMI) Drug Benefit Conference in Las Vegas earlier this week. Liston says a dominant theme at the conference...
View ArticleCatamaran posts another record year, but still has room to grow
The story of Catamaran Corp. (TSX:CCT), the giant healthcare technology company that was once known as tiny SXC Health and hailed from Milton, Ontario, isn’t familiar to most Canadian investors, but it...
View ArticleCantor Fitzgerald says buy Catamaran aggressively on Q1 selloff
Cantor Fitzgerald analyst Tom Liston says the market is overreacting to Catamaran’s (Catamaran Stock Quote, Chart, News: TSX:CCT) Q1 numbers. This morning, the company released its Q1, 2013 results....
View ArticleCatamaran’s deal with Cigna is “transformational” says Cantor Fitzgerald
Cantor Fitzgerald analysts Tom Liston and Justin Kew say Catamaran’s (Catamaran Stock Quote, Chart, News: TSX:CCT) ten-year contract with Cigna is “transformational”. Yesterday, after market, Catamaran...
View ArticleCantor Fitzgerald analyst Tom Liston continues winning ways
Cantor Fitzgerald Canada analyst Tom Liston, who came over from boutique firm Versant Partners last summer, has a hard-won reputation as a top stock picker, delivering returns against a market that has...
View ArticleIt’s time for BlackBerry to get out of the way of Canadian tech
“You’re a tech guy, huh? What about BlackBerry? Pretty bad, eh?” This is the reaction I often get when someone I meet finds out that what I do is all about Canadian technology. Today, I’m afraid to...
View ArticleIndustry trends point to growth for Catamaran, says Cantor Fitzgerald
Cantor Fitzgerald analyst Justin Kew attended the annual Pharmacy Benefit Management Institute’s Drug Benefit Conference in Las Vegas earlier this week, and came away feeling his bullish take on...
View ArticleCatamaran is compelling at 52-week low, says Cantor Fitzgerald
Down more than 20% on the year, Catamaran (TSX:CCT) is a compelling opportunity, says Cantor Fitzgerald Canada analyst Justin Kew. For the past four years, the trajectory of the company formerly known...
View ArticleCatamaran is an outstanding long-term investment, says John Zechner
Catamaran (TSX:CCT) and Google couldn’t be further apart in terms of the corners of the technology space they occupy, but they have one thing in common, says one portfolio manager; they are both...
View ArticleCatamaran spikes after $5.5-billion third quarter
Shares of Catamaran Corp. (Catamaran Corp. Stock Quote, Chart, News: TSX:CCT) are up today after the company reported Q3 results that bested expectations. Riding strong organic growth in its Pharmacy...
View Article
